A Cost-Effectiveness Analysis of EGFR-TK Mutation Status-Guided 1st- and 2nd-Line Treatment of Stage III/IV Non-Small Cell Lung Cancer in the UK
Nov 1, 2014, 00:00 AM
10.1016/j.jval.2014.08.2281
https://www.valueinhealthjournal.com/article/S1098-3015(14)04211-9/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1735
First Page :
A635
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04211-9&doi=10.1016/j.jval.2014.08.2281